DE3722383A1 - Neue verwendung von bromocriptin - Google Patents

Neue verwendung von bromocriptin

Info

Publication number
DE3722383A1
DE3722383A1 DE19873722383 DE3722383A DE3722383A1 DE 3722383 A1 DE3722383 A1 DE 3722383A1 DE 19873722383 DE19873722383 DE 19873722383 DE 3722383 A DE3722383 A DE 3722383A DE 3722383 A1 DE3722383 A1 DE 3722383A1
Authority
DE
Germany
Prior art keywords
bromocriptine
disease
therapy
autoimmune
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19873722383
Other languages
German (de)
English (en)
Inventor
Douglas Dr Larson
Peter Hiestand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of DE3722383A1 publication Critical patent/DE3722383A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE19873722383 1986-07-14 1987-07-07 Neue verwendung von bromocriptin Withdrawn DE3722383A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88511086A 1986-07-14 1986-07-14

Publications (1)

Publication Number Publication Date
DE3722383A1 true DE3722383A1 (de) 1988-01-28

Family

ID=25386156

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19873722383 Withdrawn DE3722383A1 (de) 1986-07-14 1987-07-07 Neue verwendung von bromocriptin

Country Status (13)

Country Link
JP (1) JPS6323817A (da)
KR (1) KR880001292A (da)
AU (1) AU602154B2 (da)
CH (1) CH672987A5 (da)
DE (1) DE3722383A1 (da)
DK (1) DK363887A (da)
FR (1) FR2601245A1 (da)
GB (1) GB2192541B (da)
IT (1) IT1224222B (da)
NL (1) NL8701631A (da)
PH (1) PH24525A (da)
SE (1) SE8702843L (da)
ZA (1) ZA875145B (da)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012793A1 (en) * 1991-12-23 1993-07-08 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College A therapeutic process for the treatment of the pathologies of type ii diabetes
US5866584A (en) * 1988-05-10 1999-02-02 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US6004972A (en) * 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3814521A1 (de) * 1987-05-07 1988-11-17 Sandoz Ag Neue anwendung von dopaminrezeptor-agonisten
EP0327040A3 (de) * 1988-02-05 1990-11-28 Predrag Dr.Sc. Sikiric Verwendung von Dopamin und/oder von Dopamin-Agonisten zur Herstellung eines Arzneimittels für die Behandlung des Verdauungstrakts
US5744477A (en) * 1988-05-10 1998-04-28 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for treatment of obesity using prolactin modulators and diet
US5668155A (en) * 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US5830895A (en) * 1988-05-10 1998-11-03 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for the determination and adjustment of prolactin daily rhythms
US5716932A (en) * 1988-05-10 1998-02-10 Louisiana State University And Agricultural And Mechanical College Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates
US5585347A (en) * 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5700800A (en) * 1988-05-10 1997-12-23 Ergo Science Incorporated Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
US5626860A (en) * 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
US5714519A (en) * 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
ES2425581T3 (es) 2006-11-23 2013-10-16 Sinoxa Pharma Gmbh Composiciones farmacéuticas para el tratamiento de la arteriopatía capilar
CN109689057A (zh) * 2016-04-20 2019-04-26 维罗技术有限责任公司 用于治疗代谢失调的组合物和方法
US11510921B2 (en) 2017-10-18 2022-11-29 Veroscience Llc Bromocriptine formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507249A (de) * 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
GB2154874B (en) * 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions
CH666406A5 (de) * 1984-02-29 1988-07-29 Sandoz Ag Verfahren zur herstellung von mikrokapseln, welche bromokriptinmesylat als pharmakologischen wirkstoff enthalten.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866584A (en) * 1988-05-10 1999-02-02 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US6004972A (en) * 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
WO1993012793A1 (en) * 1991-12-23 1993-07-08 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College A therapeutic process for the treatment of the pathologies of type ii diabetes

Also Published As

Publication number Publication date
GB8716323D0 (en) 1987-08-19
CH672987A5 (da) 1990-01-31
IT1224222B (it) 1990-09-26
GB2192541B (en) 1990-05-02
SE8702843L (sv) 1988-01-15
NL8701631A (nl) 1988-02-01
IT8748160A0 (it) 1987-07-10
KR880001292A (ko) 1988-04-22
AU602154B2 (en) 1990-10-04
SE8702843D0 (sv) 1987-07-13
GB2192541A (en) 1988-01-20
DK363887D0 (da) 1987-07-13
AU7558787A (en) 1988-01-21
DK363887A (da) 1988-01-15
ZA875145B (en) 1989-02-22
JPS6323817A (ja) 1988-02-01
PH24525A (en) 1990-07-18
FR2601245A1 (fr) 1988-01-15

Similar Documents

Publication Publication Date Title
DE3722383A1 (de) Neue verwendung von bromocriptin
DE3247062C2 (da)
EP1896497B1 (de) Verfahren zur diagnose von rheumatischen erkrankungen
DE3338995A1 (de) Bilobalid enthaltende arzneimittel
DE69833502T2 (de) Glucocorticoid receptor antagonisten zur behandlung von demenz
DE3526545A1 (de) Neue pharmazeutische anwendung von (nva)(pfeil hoch)2(pfeil hoch)- und dihydro-(val)(pfeil hoch)2(pfeil hoch)-cyclosporin
EP0559238A1 (de) Cyancrotonsäureamidverbindung als Arzneimittel mit immunmodulierenden Eigenschaften
Raleigh et al. Effects of chronic fenfluramine on blood serotonin, cerebrospinal fluid metabolites, and behavior in monkeys
DE69829763T2 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
DE69925488T2 (de) Verwendung von fk506 und verwandten makroliden zur herstellung eines medikaments für die behandlung und vorbeugung von schmerzen
DE3836329A1 (de) Interleukin-1 release inhibitoren
CH666188A5 (de) Immuno-regulator in form einer pharmazeutischen zusammensetzung.
WO1990014829A1 (de) Lysolecithinderivate zur behandlung von autoimmunerkrankungen
DE3390116C2 (de) Verbesserte, Koffein enthaltende, analgetische und antiinflammatorische Mittel
EP0236390B1 (de) Mittel gegen multiple sklerose
EP0541192A1 (de) Verwendung von Opiat-Antagonisten zur Behandlung von endogener Hyperinsulinämie
WO2002038150A1 (de) Aktivatoren von peroxisom-proliferator-aktivierten rezeptoren alpha, beta als arzneimittel zur behandlung von immunologisch bedingten hautstörungen
EP0398165B1 (de) Kombinationspräparate enthaltend Rifampicin und Thioacetazon sowie gegebenenfalls Isonicotinsäurehydrazid oder Ethambutol als aktive Wirkstoffe
DE2660486C2 (de) Verwendung von 2-Hydroxymethyl-3,4,5-trihydroxypiperidin als Arzneimittel
Puig-Antich et al. Growth hormone, prolactin and cortisol responses and growth patterns in hyperkinetic children treated with dextro-amphetamine: preliminary findings
DE69826285T2 (de) Verwendung von vitamin d verbindungen zur vorbeugung von transplantatabstossung
DE60020580T2 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten, die mittel, welche icam-1/lfa-1 interaktionen inhibieren und mittel, welche cd40-cd40-ligande interaktionen inhibieren, enthalten
DE69937057T2 (de) Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
DE60318916T2 (de) Ein verfahren zum screening von neuroaktiven substanzen und die assoziierte neutrale plastizität
DE2110436C3 (de) Verfahren zur Herstellung eines antileukopenischen und antikörperbildenden Thymusextrakts aus Kalbsthymus

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee